Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

LACTOSE (INDIA) LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹100.85
at close · 21 Sept 2026
▼ 0.75 (-0.74%)

Latest filings

  1. 35th AGM on Sept 30, 2026 via video conferencing; book closure from Sept 24 · Compliance
  2. Lactose India 35th AGM on 30 Sept 2026; book closure 24-30 Sept · Board & Shareholder Meetings
  3. AGM Sep 30, 2026: pay hike for two promoter directors and Rs 25 Cr related party deal · Board & Shareholder Meetings
  4. Annual Report FY26: Revenue up 39%, net profit rises 17% · Compliance
  5. Newspaper notice published for 35th AGM on September 30, 2026 · Compliance
  6. Lactose India announces 34th AGM on Sept 30 via video conferencing · Compliance
  7. Amalgamation with Vitanosh Ingredients effective from Sept 5, 2026 · Strategic Transactions
  8. Lactose India amalgamation with Vitanosh Ingredients effective · Strategic Transactions
  9. Appointment of Internal Auditor and Cost Auditor for FY 2026-27 · Management Changes
  10. Board approves audit reports, MD remuneration, new cost auditor for FY26-27 · Management Changes
  11. Board meeting outcome: auditor changes, director remuneration approved · Management Changes
  12. NCLT sanctions amalgamation of Vitanosh Ingredients into Lactose India · Strategic Transactions
  13. NCLT sanctions amalgamation of Vitanosh Ingredients into Lactose India · Strategic Transactions
  14. Lactose India Q1 FY27: Revenue up 18.7% YoY, PAT rises 57.8% · Compliance
  15. Lactose India Q1 FY27 net profit up 58 percent YoY at Rs 236.56 lakh · Compliance
  16. Q1 FY26-27: PAT up 58% YoY at Rs 236.56 lakh; revenue rises 19% · Results
  17. Q1 FY27 results: Net profit up 58% YoY to Rs 2.37 crore · Results
  18. Board Meeting on 11 Aug 2026 to Consider Q1 FY27 Results · Results
  19. CRISIL reaffirms BBB-/Stable rating; bank facilities enhanced to Rs.90 Cr · Credit & Debt
  20. RTA certificate on share dematerialization filed with BSE for Q1FY27 · Compliance
  21. Trading window closed for Q1 results till June 30, 2026 · Compliance
  22. Board forfeits 15 lakh convertible warrants · Fund Raising
  23. Board to consider forfeiting 15 lakh warrants from SG General Dealers LLP · Fund Raising
  24. We hereby submit Annual Secretarial Compliance report for financial year ended 31st March 2026. · Compliance
  25. We hereby submit Annual Secretarial Compliance report for financial year ended 31st March 2026. · Compliance
  26. Pursuant to Regulation 30 & 47(3) of SEBI (LODR) Regulations, 2015 we hereby submit the newspaper publication of financial results for quarter and year ended 31st March, 2026. · Compliance
  27. We hereby submit the Financial Results for the Quarter and Financial Year Ended 31st March, 2026 along with the Independent Auditor''s Report · Results
  28. In compliance with Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of .... · Results
  29. Lactose India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve 1. Audited Financial Results .... · Results
  30. We hereby submit our clarification on significant price movement of the company''s security. Kindly take the same on record and oblige. · Compliance
  31. The Exchange has sought clarification from Lactose India Ltd on April 24, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information .... · Compliance
  32. Pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018 we hereby submit the certificate issued by RTA. · Compliance
  33. Disclosure of Voting Results of the Extra Ordinary General Meeting of the Company held on 28th March 2026 · Board & Shareholder Meetings
  34. We hereby submit the Scrutinizer''s Report for the Extra Ordinary General Meeting held on 28th March 2026. · Board & Shareholder Meetings
  35. We hereby submit the proceeding of an Extra Ordinary General Meeting of the Company held on Saturday 28th March 2026, this meeting was convened upon the directions of the NCLT, Ahmedabad Branch. · Board & Shareholder Meetings
  36. We hereby submit the intimation towards the Closure of Trading Window for the fourth quarter and year ended 31st March 2026. · Compliance
  37. Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015 we hereby submit the newspaper publication of corrigendum notice for shareholders meeting by NCLT scheduled .... · Compliance
  38. We hereby submit the intimation towards the corrigendum notice issued for shareholders meeting to be conveyed pursuant to NCLT order, the meeting is scheduled to be held on Saturday, 28th March 2026. · Board & Shareholder Meetings
  39. Pursuant to Regulation 30 and 47(3) of SEBI (LODR) Regulations, 2015 we hereby submit the newspaper publication published in the newspaper of 27th February 2026 giving intimation of the .... · Compliance
  40. Pursuant to Regulation 30 & 42 of SEBI (LODR) Regulations 2015 we hereby submit the intimation towards the Book closure, remote e-voting. · Board & Shareholder Meetings
  41. Pursuant to the NCLT order, we hereby intimate under the Regulation 30 & 42 of SEBI (LODR) Regulations 2015, that the Extra Ordinary General Meeting of the Company is scheduled to be held .... · Board & Shareholder Meetings
  42. Pursuant to Regulation 30 & 47(3) of SEBI (LODR) Regulations, 2015 we hereby submit the newspaper publication of financial results for the quarter ended 31st December 2025. · Compliance
  43. Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015 we hereby submit the Un-Audited Financial Results along with the Limited Review Report from Statutory Auditors for the quarter .... · Results
  44. In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors .... · Results
  45. Lactose India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1. Draft Un-audited Financial .... · Results
  46. Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015 we hereby submit the intimation towards the adoption of New Line(s) of Business and Product Development / Product .... · Business Updates
  47. The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(4)(f) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, .... · Ownership Changes
  48. The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(4)(f) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for · Regulatory & Legal
  49. Pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate from RTA. · Compliance
  50. We hereby submit the intimation towards the closure of trading window for the approval of Un-Audited financial results for the quarter ended 31st December 2025. · Compliance
All filings ↓
Ask Nexa about LACTOSE (INDIA) LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures pharmaceutical products in Gujarat with a current production capacity of 10,000 metric tonnes per annum. FY26 revenue was Rs 163.29 crore, up 40.3% year-on-year, while net profit rose 17.4% to Rs 6.06 crore. EBITDA margin compressed from 14.6% in FY25 to 11.2% in FY26 as material costs rose faster than revenue. Raw materials are the largest cost, accounting for 53.6% of revenue in FY26, followed by other operating expenses at 22.4% and employee cost at 8.6%. The company is seeking NCLT and SEBI approval to amalgamate with Vitanosh Ingredients Private Limited, a related-party merger whose promoters are family members of the company's promoters, that would lift production capacity to 15,000 MT per annum. Working capital is funded through Rs 90 crore of bank facilities (long-term rating BBB-/Stable from CRISIL), including Rs 35 crore cash credit from Bank of Baroda, Rs 25 crore from YES Bank, and a Rs 30 crore term loan from Bank of Baroda.

Operating scale
Production capacity
10,000 MT per annum (rising to 15,000 MT post Vitanosh Ingredients merger)FY26
Revenue from operations
Rs 163.29 croreFY26
Net profit
Rs 6.06 croreFY26
Revenue growth, year-on-year
40.3%FY26
Bank facilities
Rs 90 crore (cash credit and term loan)FY26
Long-term credit rating
BBB-/Stable (CRISIL)July 2026
Who pays it
Pharmaceutical buyers of the company's products (no customer concentration disclosed)
Biggest cost
Raw materials, 53.6% of revenue in FY26
Kind of business
Small-cap, Gujarat-based pharmaceutical manufacturer; capacity expansion driven by related-party amalgamation
Where it sits
Listed on BSE with 10,000 MT per annum capacity; post-merger capacity to reach 15,000 MT per annum
Market Cap
₹127 Cr
P / E (TTM)
21.0×
EV / EBITDA
9.7×
Div Yield
—
Growth
36.1%▲
Revenue 5y CAGR
PAT — · EBITDA +24.4%
Quality
14.7%▲
ROCE (5y median)
ROE 8.8% · margin 11.9%
Leverage
0.95·
Debt / Equity · moderate
Net debt ₹61 Cr
Revenue FY21→FY26
4.7×▲
Margin +10.8 pts
₹35 Cr → ₹163 Cr
Cash conversion
1.44×▲
Operating cash ÷ profit · 5 yrs
₹31 Cr on ₹22 Cr
Moves on a normal day
1.86%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#62/170
P/B#52/164
ROCE#105/183
ROE#92/171
Debt / Equity#158/171
EBITDA margin#112/165
Revenue growth#16/161
Profit growth#24/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 36% a year over 5 years
Over 5 years it reported ₹22 Cr of profit and ₹31 Cr of operating cash — 1.44×
Profit is converting into cash
Concerns
Carries more debt than its peers — 0.95× equity
lower than 8% of its 171 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from LACTOSE (INDIA) LTD.'s filed financials and exchange disclosures

What does LACTOSE (INDIA) LTD. do?

LACTOSE (INDIA) LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is LACTOSE (INDIA) LTD. profitable?

Yes. Over the trailing twelve months LACTOSE (INDIA) LTD. reported a net profit of ₹6 Cr on revenue of ₹163 Cr.

Does LACTOSE (INDIA) LTD. pay a dividend?

Not in the latest reported year — LACTOSE (INDIA) LTD.'s dividend payout for FY26 was nil.

Is LACTOSE (INDIA) LTD. debt-free?

No. Debt stands at 0.95× equity, and it carries net debt of ₹61 Cr. That is lower than 8% of its 171 Pharmaceuticals peers.

Is LACTOSE (INDIA) LTD. expensive compared with its peers?

On trailing P/E, LACTOSE (INDIA) LTD. ranks 62 of 170 in Pharmaceuticals — cheaper than 64% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the LACTOSE (INDIA) LTD. share price move in a day?

On a typical session LACTOSE (INDIA) LTD. moves 1.86% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track LACTOSE (INDIA) LTD.'s announcements?

Every NSE and BSE filing by LACTOSE (INDIA) LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.